Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis.

Higher dosages of erythropoiesis-stimulating agents (ESAs) have been associated with adverse effects. Intravenous iron is used to optimize ESA response and reduces ESA doses in haemodialysis patients; this meta-analysis evaluates the magnitude of this effect.